Curis (CRIS) Publishes Preclinical Data for CUDC-305 in Clinical Cancer Research
More News related to CRIS
- Curis to Present at Piper Jaffray 21st Annual Healthcare Conference
- ThinkEquity Initiates Coverage on Curis (CRIS) with a Buy
- Curis to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Curis to Present at Merriman Curhan Ford's Investor Summit 2009
- Curis (CRIS) Posts Q3 Loss of $0.06, In-Line with Estimates
More News related to Corporate News
- Amazon.com (AMZN) To Exchange Used Textbooks for Gift Cards
- Daktronics (DAKT) To Create Large HD-16 LED Video Screen for M&T Bank Stadium, Home of the Baltimore Ravens
- Spectranetics (SPNC) Receives U.S. FDA OK for VisiSheath Dilator Sheath Device
- Highlights From ARO's Q3 Conference Call: Record Q3 Net Earning; Guides In-line for Q4
- Fuwei Films (FFHL) Receives RMB10M in Financial Support from Local Chinese Gov't
Curis, Inc. (NASDAQ: CRIS) today announced that preclinical data related to CUDC-305, the company's Heat Shock Protein 90 inhibitor, was published online this week in Clinical Cancer Research. The paper, entitled "CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacological properties for cancer therapy," will also be published in the print version of this journal shortly.
The publication reports that, in addition to potent antitumor efficacy against a broad range of cancers in preclinical tumor models as both a single agent and in combination, CUDC-305 exhibits promising pharmacological features in several areas, including high oral bioavailability, tumor selectivity, blood-brain barrier penetration, and extended retention of the compound in tumor tissue relative to normal tissue.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
